Identification

Name
Aripiprazole
Accession Number
DB01238  (APRD00638)
Type
Small Molecule
Groups
Approved, Investigational
Description

Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.

Structure
Thumb
Synonyms
  • Aripiprazol
  • Aripiprazole
  • Aripiprazolum
External IDs
OPC 31 / OPC-14597 / OPC-31
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbilifyTablet5 mg/1OralH.J. Harkins Company2002-11-15Not applicableUs
AbilifyTablet2 mgOralOtsuka Pharmaceutical Co., Ltd.2009-09-30Not applicableCanada
AbilifyTablet5 mg/1OralCardinal Health2002-11-152017-09-30Us55154 202920180913 8702 10b5lo1
AbilifyTablet30 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-172014-12-31Us
AbilifyTablet15 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-06-032014-12-31Us
AbilifyTablet, orally disintegrating15 mg/1OralOtsuka Pharmaceutical Co., Ltd.2006-06-07Not applicableUs
AbilifyTablet15 mg/1OralCarilion Materials Management2002-11-15Not applicableUs68151 446120180907 15195 bygs5j
AbilifyTablet5 mg/1Oralbryant ranch prepack2002-11-15Not applicableUs63629 338720180907 15195 5eot3c
AbilifyTablet20 mgOralOtsuka Pharmaceutical Co., Ltd.2009-09-30Not applicableCanada
AbilifyTablet30 mg/1OralAphena Pharma Solutions Tennessee, Inc.2002-11-15Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-aripiprazoleTablet30 mgOralApotex Corporation2018-04-10Not applicableCanada
Apo-aripiprazoleTablet10 mgOralApotex Corporation2018-04-10Not applicableCanada
Apo-aripiprazoleTablet20 mgOralApotex Corporation2018-04-10Not applicableCanada
Apo-aripiprazoleTablet5 mgOralApotex Corporation2018-04-10Not applicableCanada
Apo-aripiprazoleTablet15 mgOralApotex Corporation2018-04-10Not applicableCanada
Apo-aripiprazoleTablet2 mgOralApotex Corporation2018-04-10Not applicableCanada
AripiprazoleTablet2 mg/1OralSciegen Pharmaceuticals Inc.2016-09-29Not applicableUs
AripiprazoleTablet2 mg/1OralAmerincan Health Packaging2015-06-05Not applicableUs
AripiprazoleTablet, orally disintegrating10 mg/1OralAlembic Pharmaceuticals Limited2016-07-07Not applicableUs
AripiprazoleTablet10 mg/1Oralbryant ranch prepack2015-04-28Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AbilifyAripiprazole (10 mg/1)TabletOralRemedy Repack2010-12-142015-05-20Us
AbilifyAripiprazole (30 mg/1)TabletOralRemedy Repack2010-12-132014-06-21Us
AbilifyAripiprazole (15 mg/1)TabletOralRemedy Repack2010-12-142014-08-27Us
AbilifyAripiprazole (20 mg/1)TabletOralRemedy Repack2013-04-092014-08-12Us
International/Other Brands
Abilify / Abilitat
Categories
UNII
82VFR53I78
CAS number
129722-12-9
Weight
Average: 448.385
Monoisotopic: 447.148032537
Chemical Formula
C23H27Cl2N3O2
InChI Key
CEUORZQYGODEFX-UHFFFAOYSA-N
InChI
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
IUPAC Name
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
SMILES
ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl

Pharmacology

Indication

For the treatment of schizophrenia and related psychotic disorders.

Associated Conditions
Pharmacodynamics

Aripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

Mechanism of action

Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
partial agonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
partial agonist
Human
U5-hydroxytryptamine receptor 1B
antagonist
Human
U5-hydroxytryptamine receptor 1D
antagonist
Human
U5-hydroxytryptamine receptor 1E
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
antagonist
Human
U5-hydroxytryptamine receptor 6
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UD(1A) dopamine receptor
antagonist
partial agonist
Human
UD(1B) dopamine receptor
antagonist
partial agonist
Human
UD(3) dopamine receptor
antagonist
partial agonist
Human
UD(4) dopamine receptor
antagonist
partial agonist
Human
NHistamine H1 receptor
antagonist
Human
NAlpha-1A adrenergic receptor
antagonist
Human
NAlpha-1B adrenergic receptor
antagonist
Human
NAlpha-2A adrenergic receptor
antagonist
Human
NAlpha-2B adrenergic receptor
antagonist
Human
NAlpha-2C adrenergic receptor
antagonist
other/unknown
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 4.9 L/kg
Protein binding

>99%

Metabolism

Hepatic.

Route of elimination

Less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.

Half life

75-146 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Aripiprazole.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Aripiprazole.Investigational
2,5-Dimethoxy-4-ethylamphetamineAripiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineAripiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAripiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineAripiprazole may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Aripiprazole can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Aripiprazole.Approved, Investigational
AcepromazineAripiprazole may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe serum concentration of Aripiprazole can be increased when it is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Adipiplon.Investigational
AdrafinilAripiprazole may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Aripiprazole.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Aripiprazole.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alaproclate.Experimental
AlclometasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Alclometasone.Approved
AldesleukinAripiprazole may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Aripiprazole.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alimemazine.Approved, Vet Approved
AliskirenAripiprazole may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Aripiprazole.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Aripiprazole.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Aripiprazole.Approved
AmibegronAripiprazole may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineAripiprazole may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideAripiprazole may increase the hypotensive activities of Amiloride.Approved
AminoglutethimideThe serum concentration of Aripiprazole can be decreased when it is combined with Aminoglutethimide.Approved, Investigational
AmiodaroneThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideAripiprazole may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazAripiprazole may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAripiprazole may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineAripiprazole may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amobarbital.Approved, Illicit
AmoxapineAripiprazole may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amperozide.Experimental
AmphetamineThe risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BAripiprazole may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Aripiprazole is combined with Amrinone.Approved
Amyl NitriteAripiprazole may increase the hypotensive activities of Amyl Nitrite.Approved
AnagrelideAripiprazole may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodamineAripiprazole may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Aripiprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineAripiprazole may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineAripiprazole may increase the hypotensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Aripiprazole can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Aranidipine.Approved, Investigational
ArbutamineAripiprazole may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolAripiprazole may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
ArmodafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil.Approved, Investigational
ArotinololAripiprazole may increase the hypotensive activities of Arotinolol.Investigational
Arsenic trioxideAripiprazole may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Aripiprazole can be decreased when it is combined with Artemether.Approved
AsenapineAsenapine may increase the antihypertensive activities of Aripiprazole.Approved
AtazanavirThe serum concentration of Aripiprazole can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAripiprazole may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Atorvastatin.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Aripiprazole.Approved, Vet Approved
AvanafilAvanafil may increase the hypotensive activities of Aripiprazole.Approved
AvasimibeThe serum concentration of Aripiprazole can be decreased when it is combined with Avasimibe.Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Azaperone.Investigational, Vet Approved
AzatadineThe serum concentration of Aripiprazole can be decreased when it is combined with Azatadine.Approved
AzelastineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilAripiprazole may increase the hypotensive activities of Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Aripiprazole is combined with Azimilide.Investigational
AzithromycinAripiprazole may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Aripiprazole.Investigational
BambuterolAripiprazole may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.Illicit
BarnidipineAripiprazole may increase the hypotensive activities of Barnidipine.Approved
Beclomethasone dipropionateThe serum concentration of Aripiprazole can be decreased when it is combined with Beclomethasone dipropionate.Approved, Investigational
BedaquilineAripiprazole may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Aripiprazole.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Aripiprazole.Investigational
BenazeprilAripiprazole may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Aripiprazole is combined with Bencyclane.Experimental
BendroflumethiazideAripiprazole may increase the hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Aripiprazole.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineAripiprazole may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilAripiprazole may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Aripiprazole.Approved, Investigational
BetamethasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
BevantololAripiprazole may increase the antihypertensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Aripiprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Aripiprazole is combined with Bioallethrin.Approved, Experimental
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aripiprazole.Approved
BisoprololAripiprazole may increase the hypotensive activities of Bisoprolol.Approved
BitolterolAripiprazole may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Aripiprazole can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved
BortezomibThe metabolism of Aripiprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Aripiprazole can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum Toxin Type B.Approved, Investigational
BretyliumAripiprazole may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleAripiprazole may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
BromazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromisoval.Experimental
BromocriptineAripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Aripiprazole.Investigational
BudesonideThe serum concentration of Aripiprazole can be decreased when it is combined with Budesonide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Aripiprazole.Investigational, Withdrawn
BufuralolBufuralol may increase the orthostatic hypotensive activities of Aripiprazole.Experimental, Investigational
BumetanideAripiprazole may increase the hypotensive activities of Bumetanide.Approved
BunazosinBunazosin may increase the antihypertensive activities of Aripiprazole.Investigational
BupivacaineAripiprazole may increase the hypotensive activities of Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved
BuprenorphineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Aripiprazole can be increased when it is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aripiprazole.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aripiprazole.Approved
CalcitriolThe metabolism of Aripiprazole can be increased when combined with Calcitriol.Approved, Nutraceutical
CanagliflozinAripiprazole may increase the hypotensive activities of Canagliflozin.Approved
Candesartan cilexetilAripiprazole may increase the hypotensive activities of Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Canertinib.Investigational
CaptoprilAripiprazole may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinAripiprazole may increase the hypotensive activities of Carbetocin.Approved, Investigational
CarbidopaThe therapeutic efficacy of Carbidopa can be decreased when used in combination with Aripiprazole.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Carboxyamidotriazole.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Aripiprazole.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Caroverine.Experimental
CarteololAripiprazole may increase the hypotensive activities of Carteolol.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Aripiprazole.Experimental
CefradineThe serum concentration of Aripiprazole can be decreased when it is combined with Cefradine.Approved
CelecoxibThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
CeritinibThe serum concentration of Aripiprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Cerivastatin.Approved, Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cetirizine.Approved
CevimelineThe metabolism of Aripiprazole can be decreased when combined with Cevimeline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aripiprazole.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Aripiprazole can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideAripiprazole may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorphenamine.Approved
ChlorphenesinThe serum concentration of Aripiprazole can be decreased when it is combined with Chlorphenesin.Approved, Experimental
ChlorphentermineAripiprazole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneAripiprazole may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Aripiprazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Aripiprazole.Experimental
CilazaprilAripiprazole may increase the hypotensive activities of Cilazapril.Approved
CilnidipineAripiprazole may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ciprofloxacin.Approved, Investigational
CirazolineAripiprazole may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideAripiprazole may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Aripiprazole can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Aripiprazole can be increased when it is combined with Clemastine.Approved, Investigational
ClenbuterolAripiprazole may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineAripiprazole may increase the hypotensive activities of Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clindamycin.Approved, Vet Approved
ClobazamThe serum concentration of Aripiprazole can be decreased when it is combined with Clobazam.Approved, Illicit
Clobetasol propionateThe metabolism of Aripiprazole can be increased when combined with Clobetasol propionate.Approved
ClofarabineAripiprazole may increase the hypotensive activities of Clofarabine.Approved, Investigational
ClofibrateThe serum concentration of Aripiprazole can be decreased when it is combined with Clofibrate.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with clomethiazole.Investigational
ClomipramineThe serum concentration of Aripiprazole can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clonazepam.Approved, Illicit
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Aripiprazole.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Aripiprazole.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aripiprazole.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Aripiprazole can be decreased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Aripiprazole can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Aripiprazole can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Aripiprazole can be decreased when it is combined with Colchicine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Aripiprazole.Approved, Investigational
CrizotinibThe serum concentration of Aripiprazole can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Aripiprazole can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Aripiprazole is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclobenzaprine.Approved
CyclophosphamideThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclophosphamide.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclopropane.Experimental
CyclosporineThe serum concentration of Aripiprazole can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Aripiprazole can be increased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Aripiprazole can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.Approved, Investigational
DapagliflozinAripiprazole may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Aripiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Aripiprazole.Investigational
DarifenacinThe serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Darodipine.Experimental
DarunavirThe serum concentration of Aripiprazole can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelafloxacinThe serum concentration of Aripiprazole can be decreased when it is combined with Delafloxacin.Approved, Investigational
DelavirdineThe serum concentration of Aripiprazole can be increased when it is combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Aripiprazole.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Deramciclane.Investigational
DesfluraneAripiprazole may increase the hypotensive activities of Desflurane.Approved
DesipramineThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desloratadine.Approved, Investigational
DesogestrelThe metabolism of Aripiprazole can be decreased when combined with Desogestrel.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine.Approved
DexmedetomidineAripiprazole may increase the hypotensive activities of Dexmedetomidine.Approved, Vet Approved
DexniguldipineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Dexniguldipine.Experimental
DextroamphetamineAripiprazole may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with Aripiprazole.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe serum concentration of Aripiprazole can be decreased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe risk or severity of hypotension can be increased when Aripiprazole is combined with Dexverapamil.Experimental
DezocineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Aripiprazole.Approved, Illicit, Investigational, Vet Approved
DiclofenamideAripiprazole may increase the hypotensive activities of Diclofenamide.Approved, Investigational
DicloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Dicloxacillin.Approved, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Aripiprazole.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Aripiprazole can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Aripiprazole can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Dimenhydrinate.Approved
DinutuximabAripiprazole may increase the hypotensive activities of Dinutuximab.Approved, Investigational
DiphenhydramineThe serum concentration of Aripiprazole can be increased when it is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aripiprazole.Approved, Illicit
DipivefrinAripiprazole may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleAripiprazole may increase the hypotensive activities of Dipyridamole.Approved
DisopyramideAripiprazole may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dixyrazine.Experimental
DL-MethylephedrineAripiprazole may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineAripiprazole may decrease the vasoconstricting activities of Dobutamine.Approved
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Aripiprazole.Approved
DofetilideThe metabolism of Dofetilide can be decreased when combined with Aripiprazole.Approved, Investigational
DolasetronAripiprazole may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneAripiprazole may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopexamineAripiprazole may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Aripiprazole can be increased when it is combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Dotarizine.Investigational
DoxepinThe serum concentration of Aripiprazole can be increased when it is combined with Doxepin.Approved, Investigational
DoxofyllineAripiprazole may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe serum concentration of Aripiprazole can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Aripiprazole is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Illicit
DronedaroneThe serum concentration of Aripiprazole can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
DrospirenoneThe serum concentration of Aripiprazole can be decreased when it is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Drotebanol.Experimental, Illicit
DroxidopaAripiprazole may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Aripiprazole.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineAripiprazole may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Aripiprazole can be decreased when it is combined with Eletriptan.Approved, Investigational
EliglustatThe serum concentration of Aripiprazole can be increased when it is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Eltanolone.Investigational
EmopamilThe risk or severity of hypotension can be increased when Aripiprazole is combined with Emopamil.Experimental
EmpagliflozinAripiprazole may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilAripiprazole may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAripiprazole may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe serum concentration of Aripiprazole can be decreased when it is combined with Enasidenib.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Enflurane.Approved, Investigational, Vet Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Aripiprazole.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Aripiprazole.Experimental
EperisoneThe risk or severity of hypotension can be increased when Aripiprazole is combined with Eperisone.Approved, Investigational
EphedraAripiprazole may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineAripiprazole may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineAripiprazole may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Aripiprazole.Approved, Vet Approved
EplerenoneAripiprazole may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolAripiprazole may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAripiprazole may increase the hypotensive activities of Eprosartan.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Aripiprazole.Approved, Nutraceutical
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aripiprazole.Approved
ErythromycinThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Aripiprazole.Experimental
EscitalopramAripiprazole may increase the antihypertensive activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Aripiprazole.Approved, Illicit
EstradiolThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol dienanthate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aripiprazole.Approved, Investigational
Etacrynic acidAripiprazole may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
EtafedrineAripiprazole may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Aripiprazole.Approved
EthosuximideThe risk or severity of hypotension can be increased when Aripiprazole is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etifoxine.Investigational, Withdrawn
EtilefrineAripiprazole may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etizolam.Approved
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Aripiprazole.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etoperidone.Withdrawn
EtoposideThe metabolism of Aripiprazole can be increased when combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Aripiprazole can be decreased when it is combined with Etravirine.Approved
ExemestaneThe serum concentration of Aripiprazole can be decreased when it is combined with Exemestane.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Aripiprazole.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ezogabine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole.Approved
FelbamateThe serum concentration of Aripiprazole can be decreased when it is combined with Felbamate.Approved
FelodipineAripiprazole may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Fendiline.Withdrawn
FenoldopamAripiprazole may increase the hypotensive activities of Fenoldopam.Approved
FenoterolAripiprazole may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Aripiprazole.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fexofenadine.Approved, Investigational
FimasartanAripiprazole may increase the hypotensive activities of Fimasartan.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Aripiprazole is combined with Fish oil.Approved, Nutraceutical
FlecainideAripiprazole may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluanisone.Experimental
FlucloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FluconazoleThe metabolism of Aripiprazole can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Flunarizine.Approved
FlunisolideThe metabolism of Aripiprazole can be increased when combined with Flunisolide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunitrazepam.Approved, Illicit
Fluocinolone acetonideThe serum concentration of Aripiprazole can be decreased when it is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluorouracilThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.Approved, Vet Approved
FlupentixolFlupentixol may increase the antihypertensive activities of Aripiprazole.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aripiprazole.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Aripiprazole can be increased when combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Aripiprazole.Approved, Nutraceutical, Vet Approved
FormoterolAripiprazole may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Aripiprazole can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Aripiprazole can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilAripiprazole may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Aripiprazole.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Aripiprazole.Approved, Investigational
FurosemideAripiprazole may increase the hypotensive activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Aripiprazole can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Gabapentin enacarbilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidAripiprazole may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Aripiprazole is combined with Gallopamil.Investigational
Gamma hydroxybutyric acidThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemfibrozilThe serum concentration of Aripiprazole can be decreased when it is combined with Gemfibrozil.Approved
GemifloxacinAripiprazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GentamicinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gentamicin.Approved, Vet Approved
GepefrineAripiprazole may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Aripiprazole.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Aripiprazole.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.Approved, Investigational
Glucagon recombinantAripiprazole may increase the gastrointestinal motility reducing activities of Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Aripiprazole.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Aripiprazole.Approved, Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Goserelin.Approved
GranisetronAripiprazole may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GriseofulvinThe serum concentration of Aripiprazole can be decreased when it is combined with Griseofulvin.Approved, Investigational, Vet Approved
GuanabenzAripiprazole may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanethidineThe serum concentration of Aripiprazole can be decreased when it is combined with Guanethidine.Approved
GuanfacineAripiprazole may increase the hypotensive activities of Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Aripiprazole.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolAripiprazole may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneAripiprazole may increase the hypotensive activities of Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Hexobarbital.Approved
HexoprenalineAripiprazole may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineAripiprazole may decrease the vasoconstricting activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole.Approved, Investigational
HydralazineAripiprazole may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideAripiprazole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HydrocortamateThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortamate.Approved
HydrocortisoneThe metabolism of Aripiprazole can be increased when combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideAripiprazole may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineAripiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Aripiprazole.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole.Approved, Investigational
IbutilideAripiprazole may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Aripiprazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Aripiprazole can be decreased when it is combined with Ifosfamide.Approved
IloperidoneAripiprazole may increase the antihypertensive activities of Iloperidone.Approved
IloprostAripiprazole may increase the hypotensive activities of Iloprost.Approved, Investigational
ImatinibThe serum concentration of Aripiprazole can be increased when it is combined with Imatinib.Approved
ImidaprilAripiprazole may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.Approved
IndacaterolAripiprazole may decrease the vasoconstricting activities of Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indalpine.Investigational, Withdrawn
IndapamideAripiprazole may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Aripiprazole.Withdrawn
IndinavirThe serum concentration of Aripiprazole can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indiplon.Investigational
IndoraminAripiprazole may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Aripiprazole.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Aripiprazole.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Aripiprazole.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Aripiprazole.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Aripiprazole.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Aripiprazole.Approved
Iofetamine I-123Aripiprazole may decrease the stimulatory activities of Iofetamine I-123.Approved
IpratropiumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ipratropium.Approved
IrbesartanAripiprazole may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Aripiprazole can be decreased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Aripiprazole can be increased when used in combination with Isocarboxazid.Approved
IsoetarineAripiprazole may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Aripiprazole.Approved, Vet Approved
IsomethepteneAripiprazole may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe serum concentration of Aripiprazole can be increased when it is combined with Isoniazid.Approved, Investigational
IsoprenalineThe therapeutic efficacy of Isoprenaline can be decreased when used in combination with Aripiprazole.Approved, Investigational
Isosorbide dinitrateAripiprazole may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateAripiprazole may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineAripiprazole may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineAripiprazole may increase the hypotensive activities of Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Aripiprazole can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Aripiprazole can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ketoconazole.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ketotifen.Approved
L-TryptophanThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Aripiprazole.Approved, Nutraceutical, Withdrawn
LacidipineAripiprazole may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Aripiprazole.Approved
LamotrigineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Aripiprazole.Investigational
LansoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
LenvatinibAripiprazole may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineAripiprazole may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Aripiprazole is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
LevobunololAripiprazole may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineAripiprazole may increase the hypotensive activities of Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocetirizine.Approved
LevodopaAripiprazole may increase the hypotensive activities of Levodopa.Approved
LevofloxacinAripiprazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl acetateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aripiprazole.Approved
LevosalbutamolAripiprazole may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevosimendanAripiprazole may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Lidoflazine.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Aripiprazole.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aripiprazole.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Aripiprazole.Approved
LisdexamfetamineAripiprazole may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilAripiprazole may increase the hypotensive activities of Lisinopril.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lithium carbonate.Approved
Lithium cationLithium may increase the neurotoxic activities of Aripiprazole.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lofentanil.Illicit
LofexidineAripiprazole may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomerizineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Lomerizine.Experimental
LoperamideThe risk or severity of hypotension can be increased when Aripiprazole is combined with Loperamide.Approved
LopinavirThe serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Loprazolam.Experimental
LoratadineThe serum concentration of Aripiprazole can be decreased when it is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.Approved
LorcaserinThe serum concentration of Aripiprazole can be increased when it is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lorpiprazole.Approved
LosartanAripiprazole may increase the hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Aripiprazole can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aripiprazole.Approved
LuliconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Aripiprazole can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Aripiprazole can be decreased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lurasidone.Approved, Investigational
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Aripiprazole.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Aripiprazole.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aripiprazole.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Aripiprazole can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Magnesium Trisilicate.Approved
ManidipineThe serum concentration of Aripiprazole can be increased when it is combined with Manidipine.Approved, Investigational
MannitolAripiprazole may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Maprotiline.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mebicar.Experimental
MecamylamineAripiprazole may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Aripiprazole is combined with Menthol.Approved
MephedroneAripiprazole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAripiprazole may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Aripiprazole.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Mepyramine.Approved, Vet Approved
MequitazineAripiprazole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mesoridazine.Approved, Investigational
MetamizoleThe serum concentration of Aripiprazole can be decreased when it is combined with Metamizole.Approved, Investigational, Withdrawn
MetaraminolAripiprazole may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
Methadyl acetateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineAripiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methaqualone.Illicit, Withdrawn
MethazolamideAripiprazole may increase the hypotensive activities of Methazolamide.Approved
MethimazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methimazole.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Aripiprazole.Approved
MethotrimeprazineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineAripiprazole may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineAripiprazole may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Aripiprazole is combined with Methsuximide.Approved
MethyclothiazideAripiprazole may increase the hypotensive activities of Methyclothiazide.Approved
MethyldopaAripiprazole may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Aripiprazole can be decreased when it is combined with Methylprednisolone.Approved, Vet Approved
MetipranololAripiprazole may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.Approved, Investigational
MetoclopramideThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneAripiprazole may increase the hypotensive activities of Metolazone.Approved
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Aripiprazole.Approved
MetyraponeThe serum concentration of Aripiprazole can be decreased when it is combined with Metyrapone.Approved, Investigational
MetyrosineAripiprazole may increase the sedative activities of Metyrosine.Approved
MibefradilThe serum concentration of Aripiprazole can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Aripiprazole can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.Approved, Illicit
MidodrineAripiprazole may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineAripiprazole may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Aripiprazole can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Aripiprazole can be decreased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Aripiprazole.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Milnacipran.Approved, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aripiprazole.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
MinoxidilAripiprazole may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirabegronThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Aripiprazole.Investigational
MirtazapineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
MitotaneThe serum concentration of Aripiprazole can be decreased when it is combined with Mitotane.Approved
MMDAAripiprazole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aripiprazole.Approved, Investigational
ModafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilAripiprazole may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Molindone.Approved
MorphineAripiprazole may increase the hypotensive activities of Morphine.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Moxifloxacin.Approved, Investigational
MoxonidineAripiprazole may increase the hypotensive activities of Moxonidine.Approved, Investigational
MyrrhThe serum concentration of Aripiprazole can be decreased when it is combined with Myrrh.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
NadololAripiprazole may increase the hypotensive activities of Nadolol.Approved
NafcillinThe serum concentration of Aripiprazole can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftopidilThe risk or severity of hypotension can be increased when Aripiprazole is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Nalbuphine.Approved
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Aripiprazole.Approved, Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
NebivololAripiprazole may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Aripiprazole can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir.Approved
NeomycinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Neomycin.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NesiritideAripiprazole may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Aripiprazole can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Aripiprazole can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Aripiprazole can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
NifedipineThe serum concentration of Aripiprazole can be decreased when it is combined with Nifedipine.Approved
NiguldipineAripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Aripiprazole can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Niludipine.Experimental
NilvadipineAripiprazole may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Aripiprazole is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineAripiprazole may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineAripiprazole may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrazepam.Approved
NitrendipineAripiprazole may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideAripiprazole may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinAripiprazole may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideAripiprazole may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidAripiprazole may increase the hypotensive activities of Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nordazepam.Approved
NorepinephrineAripiprazole may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineAripiprazole may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfluraneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Norflurane.Approved, Investigational
NorgestimateThe serum concentration of Aripiprazole can be decreased when it is combined with Norgestimate.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Normethadone.Approved, Illicit
NortriptylineAripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Aripiprazole.Approved
ObinutuzumabAripiprazole may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctopamineAripiprazole may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideThe metabolism of Aripiprazole can be decreased when combined with Octreotide.Approved, Investigational
OfloxacinAripiprazole may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineAripiprazole may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Aripiprazole can be increased when it is combined with Olaparib.Approved
OlmesartanAripiprazole may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolAripiprazole may decrease the vasoconstricting activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Aripiprazole.Approved
OpiumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Opium.Approved, Illicit
OrciprenalineAripiprazole may decrease the vasoconstricting activities of Orciprenaline.Approved
OritavancinThe serum concentration of Aripiprazole can be decreased when it is combined with Oritavancin.Approved, Investigational
OrlistatThe serum concentration of Aripiprazole can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Aripiprazole can be decreased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Aripiprazole is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aripiprazole.Approved
OxcarbazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine.Approved
OxiconazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Oxiconazole.Approved
OxprenololAripiprazole may increase the hypotensive activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Aripiprazole.Approved, Illicit, Investigational
OxyfedrineAripiprazole may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole.Approved, Vet Approved
PaclitaxelThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePaliperidone may increase the antihypertensive activities of Aripiprazole.Approved
PanobinostatThe serum concentration of Aripiprazole can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Papaverine.Approved, Investigational
ParaldehydeAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Aripiprazole.Approved, Investigational
PazopanibAripiprazole may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Aripiprazole can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe metabolism of Aripiprazole can be increased when combined with Pegvisomant.Approved
PenbutololAripiprazole may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of hypotension can be increased when Aripiprazole is combined with Penfluridol.Experimental
PentamidineAripiprazole may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.Approved, Vet Approved
PentobarbitalThe serum concentration of Aripiprazole can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Aripiprazole.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
PerazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perazine.Approved, Investigational
PerflutrenAripiprazole may increase the QTc-prolonging activities of Perflutren.Approved
PergolideAripiprazole may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilAripiprazole may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Aripiprazole.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aripiprazole.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenazocine.Experimental
PhendimetrazineAripiprazole may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineAripiprazole may increase the hypotensive activities of Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Aripiprazole.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenibut.Experimental
PheniramineThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pheniramine.Approved
PhenobarbitalThe serum concentration of Aripiprazole can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenoperidine.Experimental
PhenoxybenzamineAripiprazole may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenoxyethanol.Approved
PhentermineThe risk or severity of serotonin syndrome can be increased when Phentermine is combined with Aripiprazole.Approved, Illicit
PhentolamineAripiprazole may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Phenylbutazone.Approved, Vet Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Aripiprazole.Approved
PhenylpropanolamineAripiprazole may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideAripiprazole may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Aripiprazole is combined with Pinaverium.Approved
PindololAripiprazole may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneAripiprazole may increase the hypotensive activities of Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipotiazine.Approved, Investigational
PirbuterolAripiprazole may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Aripiprazole.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Aripiprazole.Approved, Investigational
PizotifenAripiprazole may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Aripiprazole.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideThe risk or severity of gastrointestinal ulceration can be increased when Aripiprazole is combined with Potassium Chloride.Approved, Withdrawn
PractololPractolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved
PramipexoleAripiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Aripiprazole.Approved, Investigational
PravastatinThe metabolism of Pravastatin can be decreased when combined with Aripiprazole.Approved
PrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam.Approved, Illicit
PrednisoloneThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Aripiprazole can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolAripiprazole may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prilocaine.Approved
PrimaquineAripiprazole may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Aripiprazole can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Aripiprazole can be decreased when it is combined with Probenecid.Approved, Investigational
ProcainamideAripiprazole may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aripiprazole.Approved, Investigational
ProcaterolAripiprazole may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.Approved, Vet Approved
ProgesteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Aripiprazole.Approved, Investigational
PropafenoneThe serum concentration of Aripiprazole can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Proparacaine.Approved, Vet Approved
PropericiazineAripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Aripiprazole.Approved
PropiverineAripiprazole may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolAripiprazole may increase the hypotensive activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
ProtokylolAripiprazole may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Aripiprazole is combined with PSD502.Investigational
PseudoephedrineThe risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pyrantel.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quazepam.Approved, Illicit
QuetiapineAripiprazole may increase the hypotensive activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Aripiprazole.Approved, Investigational
QuinaprilAripiprazole may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Aripiprazole can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Aripiprazole can be decreased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quinisocaine.Experimental
RacepinephrineAripiprazole may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Raclopride.Investigational
RactopamineAripiprazole may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon.Approved, Investigational
RamiprilAripiprazole may increase the hypotensive activities of Ramipril.Approved
RanitidineThe serum concentration of Aripiprazole can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Aripiprazole can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineAripiprazole may increase the hypotensive activities of Rasagiline.Approved
RemifentanilAripiprazole may increase the hypotensive activities of Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ReproterolAripiprazole may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe serum concentration of Aripiprazole can be decreased when it is combined with Reserpine.Approved, Investigational
RifabutinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Aripiprazole can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineAripiprazole may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Aripiprazole can be decreased when it is combined with Rilpivirine.Approved
RimiterolAripiprazole may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatAripiprazole may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe serum concentration of Aripiprazole can be increased when it is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritanserin.Investigational
RitobegronAripiprazole may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineAripiprazole may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aripiprazole.Approved
RofecoxibThe serum concentration of Aripiprazole can be decreased when it is combined with Rofecoxib.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Aripiprazole can be increased when it is combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Romifidine.Vet Approved
RopiniroleAripiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineAripiprazole may increase the hypotensive activities of Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aripiprazole.Approved, Investigational
RotigotineAripiprazole may increase the sedative activities of Rotigotine.Approved
RucaparibThe serum concentration of Aripiprazole can be increased when it is combined with Rucaparib.Approved, Investigational
RufinamideThe serum concentration of Aripiprazole can be decreased when it is combined with Rufinamide.Approved
SacubitrilAripiprazole may increase the hypotensive activities of Sacubitril.Approved
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Aripiprazole.Approved, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Aripiprazole.Approved
SaquinavirThe serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aripiprazole.Approved, Vet Approved
SelegilineAripiprazole may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Aripiprazole is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sepranolone.Investigational
SeratrodastThe serum concentration of Aripiprazole can be decreased when it is combined with Seratrodast.Approved
SertindoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertindole.Approved, Investigational, Withdrawn
SevofluraneAripiprazole may increase the hypotensive activities of Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Aripiprazole.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Aripiprazole.Approved
SiltuximabThe serum concentration of Aripiprazole can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Aripiprazole can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aripiprazole.Approved
SolabegronAripiprazole may decrease the vasoconstricting activities of Solabegron.Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Aripiprazole.Investigational
SotalolAripiprazole may increase the hypotensive activities of Sotalol.Approved
SpironolactoneAripiprazole may increase the hypotensive activities of Spironolactone.Approved
St. John's WortThe serum concentration of Aripiprazole can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Aripiprazole can be increased when it is combined with Stiripentol.Approved
StreptokinaseAripiprazole may increase the hypotensive activities of Streptokinase.Approved, Investigational
SuccinylcholineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Succinylcholine.Approved
SufentanilAripiprazole may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aripiprazole.Approved, Investigational
SulpirideAripiprazole may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole.Approved, Investigational
SuvorexantAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineAripiprazole may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Aripiprazole.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Aripiprazole.Investigational
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Aripiprazole.Approved
TamsulosinAripiprazole may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tasimelteon.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aripiprazole.Approved
TelaprevirThe serum concentration of Aripiprazole can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinAripiprazole may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Telithromycin.Approved
TelmisartanAripiprazole may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Aripiprazole.Approved, Investigational
TemozolomideThe serum concentration of Aripiprazole can be decreased when it is combined with Temozolomide.Approved, Investigational
TerazosinAripiprazole may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Aripiprazole can be increased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Aripiprazole.Approved
TerfenadineThe serum concentration of Aripiprazole can be decreased when it is combined with Terfenadine.Approved, Withdrawn
TerodilineThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Aripiprazole.Experimental
TesmilifeneThe serum concentration of Aripiprazole can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Testosterone.Approved, Investigational
Testosterone undecanoateThe serum concentration of Aripiprazole can be decreased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Tetrandrine.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrodotoxin.Investigational
TetryzolineAripiprazole may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe risk or severity of hypotension, dyspepsia, and headache can be increased when Theophylline is combined with Aripiprazole.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiopental.Approved, Vet Approved
ThioproperazineAripiprazole may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Aripiprazole.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiapride.Approved, Investigational
TiclopidineThe serum concentration of Aripiprazole can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tilidine.Experimental
TipranavirThe serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineAripiprazole may increase the hypotensive activities of Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.Approved, Investigational
TolazolineAripiprazole may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.Approved, Investigational
TolcaponeAripiprazole may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Aripiprazole is combined with Tolfenamic Acid.Approved, Investigational
TopiramateThe serum concentration of Aripiprazole can be decreased when it is combined with Topiramate.Approved
TopotecanThe serum concentration of Aripiprazole can be decreased when it is combined with Topotecan.Approved, Investigational
TorasemideAripiprazole may increase the hypotensive activities of Torasemide.Approved
ToremifeneAripiprazole may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.Approved, Investigational
TrametinibThe serum concentration of Aripiprazole can be decreased when it is combined with Trametinib.Approved
TrandolaprilAripiprazole may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Aripiprazole is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of serotonin syndrome can be increased when Tranylcypromine is combined with Aripiprazole.Approved, Investigational
TrazodoneTrazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.Approved, Investigational
TretinoinAripiprazole may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolAripiprazole may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamcinoloneThe serum concentration of Aripiprazole can be decreased when it is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAripiprazole may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Aripiprazole.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Aripiprazole.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Aripiprazole.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Aripiprazole is combined with Trimethadione.Approved
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Aripiprazole.Approved, Vet Approved
TrimipramineAripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triprolidine.Approved
TroglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Troglitazone.Investigational, Withdrawn
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Aripiprazole.Approved
TulobuterolAripiprazole may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Aripiprazole.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Aripiprazole.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Valproic Acid.Approved, Investigational
ValsartanAripiprazole may increase the hypotensive activities of Valsartan.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vancomycin.Approved
VandetanibAripiprazole may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Aripiprazole.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aripiprazole.Approved
VenlafaxineThe serum concentration of Aripiprazole can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Veralipride.Experimental
VerapamilThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vigabatrin.Approved
VilanterolAripiprazole may decrease the vasoconstricting activities of Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Aripiprazole.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Aripiprazole.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Aripiprazole is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Aripiprazole.Approved, Investigational
VoriconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of Tachycardia and drowsiness can be increased when Aripiprazole is combined with WIN 55212-2.Experimental
XamoterolAripiprazole may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Xylazine.Vet Approved
XylometazolineAripiprazole may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
YohimbineThe risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Aripiprazole is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zimelidine.Withdrawn
ZincThe therapeutic efficacy of Zinc can be decreased when used in combination with Aripiprazole.Approved, Investigational
ZiprasidoneThe serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aripiprazole.Approved, Investigational
ZolpidemAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of hypotension can be increased when Aripiprazole is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Aripiprazole.Approved
ZotepineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolAripiprazole may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol (possible additive effect to CNS).
  • Food has no significant effect on absorption.
  • Take without regard to meals.

References

Synthesis Reference
US5006528
General References
Not Available
External Links
Human Metabolome Database
HMDB0005042
KEGG Drug
D01164
KEGG Compound
C12564
PubChem Compound
60795
PubChem Substance
46505745
ChemSpider
54790
BindingDB
50130293
ChEBI
31236
ChEMBL
CHEMBL1112
Therapeutic Targets Database
DAP000076
PharmGKB
PA10026
IUPHAR
34
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Aripiprazole
ATC Codes
N05AX12 — Aripiprazole
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (262 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableBipolar Disorder (BD)1
1CompletedNot AvailableDepressive Disorders1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
1CompletedNot AvailableSchizophrenic Disorders1
1CompletedBasic ScienceAlzheimer's Disease (AD)1
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceSchizophrenic Disorders1
1CompletedOtherAntipsychotics / Immunoassay1
1CompletedSupportive CareSchizophrenic Disorders1
1CompletedTreatmentCocaine-Related Disorders1
1CompletedTreatmentHealthy Male Adults1
1CompletedTreatmentNervous System Diseases / Psychiatric Disorder NOS / Schizophrenic Disorders1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders5
1Not Yet RecruitingOtherSchizophrenic Disorders1
1RecruitingOtherSchizophrenic Disorders1
1Unknown StatusTreatmentAmphetamine-Related Disorders1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
2CompletedTreatmentAcute Schizophrenia / Schizoaffective Disorders1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAsperger's Disorder / Autism, Early Infantile / Pervasive Developmental Disorder NOS1
2CompletedTreatmentAsperger's Disorder / Pervasive Developmental Disorder NOS1
2CompletedTreatmentAsperger's Syndrome / Autism Spectrum Conditions/Disorders / Autistic Disorder1
2CompletedTreatmentAutism, Early Infantile1
2CompletedTreatmentBehavioral Problems Associated With Fragile X Syndrome / Fragile X Syndrome (FXS)1
2CompletedTreatmentBipolar I Disorder / Major Depressive Disorder (MDD) / Schizophrenic Disorders1
2CompletedTreatmentCocaine Abuse1
2CompletedTreatmentDepression1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Substance Abuse1
2CompletedTreatmentMania / Schizophrenic Disorders1
2CompletedTreatmentPTSD1
2CompletedTreatmentSchizophrenic Disorders3
2RecruitingTreatmentAutism Spectrum Conditions/Disorders1
2RecruitingTreatmentSchizophrenic Disorders1
2TerminatedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2Unknown StatusTreatmentDependence, Cocaine / Schizophrenic Disorders1
2WithdrawnTreatmentBipolar 1 Disorder / Nervous System Diseases / Psychiatric Disorder NOS / Schizophrenic Disorders1
2, 3CompletedTreatmentAlcohol Dependence1
2, 3CompletedTreatmentPsychosis / Schizophrenic Disorders1
2, 3CompletedTreatmentSchizophrenic Disorders2
2, 3Not Yet RecruitingTreatmentPharmacotherapy / Schizophrenia and Related Disorders / Stimulant Abuse / Stimulant Dependence / Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis)1
2, 3TerminatedTreatmentSchizophrenic Disorders1
2, 3WithdrawnTreatmentDiabetes Mellitus (DM)1
3Active Not RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3Active Not RecruitingTreatmentSchizophrenic Disorders1
3CompletedNot AvailableSchizophrenia and Schizoaffective Disorder1
3CompletedDiagnosticMajor Depressive Disorder (MDD)2
3CompletedPreventionBipolar Disorder (BD)1
3CompletedTreatmentAlcohol Dependence1
3CompletedTreatmentAlzheimer's Disease (AD)2
3CompletedTreatmentAlzheimer's Disease (AD) / Dementias1
3CompletedTreatmentAutistic Disorder4
3CompletedTreatmentAutistic Disorder / Behavioral Symptoms2
3CompletedTreatmentBipolar Disorder (BD)9
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar Disorder Mania1
3CompletedTreatmentBipolar I1
3CompletedTreatmentBipolar I Disorder6
3CompletedTreatmentBody Weight Changes / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentChronic Motor or Vocal Tic Disorder / Tourette's Disorder1
3CompletedTreatmentDementia, Alzheimer Type1
3CompletedTreatmentMajor Depressive Disorder (MDD)6
3CompletedTreatmentPervasive Developmental Disorder NOS1
3CompletedTreatmentPostpartum Depression1
3CompletedTreatmentPosttraumatic Stress Disorders1
3CompletedTreatmentPsychotic Depression1
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders20
3CompletedTreatmentTic Disorders / Tourette's Disorder2
3CompletedTreatmentTourette's Disorder3
3RecruitingTreatmentAlcohol Abuse / Alcoholism / Bipolar Disorder (BD)1
3RecruitingTreatmentAutistic Disorder1
3RecruitingTreatmentDepression, Bipolar1
3RecruitingTreatmentGilles de la Tourette's Syndrome1
3RecruitingTreatmentSchizophrenic Disorders3
3TerminatedTreatmentAcute Depressive Episode / Bipolar Disorder (BD)1
3TerminatedTreatmentAdolescent Schizophrenia / Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features1
3TerminatedTreatmentAgitation Associated With Dementia of the Alzheimer's Type1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar I Disorder / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentMajor Depressive Disorder (MDD)3
3TerminatedTreatmentSchizophrenic Disorders3
3TerminatedTreatmentTherapy-Resistant Depression1
3Unknown StatusTreatmentAnorexia Nervosa (AN)1
3Unknown StatusTreatmentPsychosis Nos/Other1
3WithdrawnTreatmentBipolar Disorder (BD)1
4CompletedNot AvailableBipolar Disorder (BD) / Schizophrenic Disorders1
4CompletedNot AvailableMoods Disorders / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4CompletedBasic ScienceCYP3A4 Protein, Human / Cytochrome P-450 CYP2D6 / Pharmacokinetics1
4CompletedBasic ScienceDiabetes Mellitus (DM)2
4CompletedBasic SciencePsychosis / Schizophrenic Disorders1
4CompletedPreventionSchizophrenic Disorders1
4CompletedSupportive CareAutistic Disorder1
4CompletedTreatmentAggressive Behavior / Attention Deficit Disorder With Hyperactivity (ADHD) / Attention Deficit-Hyperactivity / Bipolar Disorder (BD) / Oppositional Defiant Disorder / PDD / Pervasive Development Disorders1
4CompletedTreatmentAlcoholism1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Schizophrenic Disorders1
4CompletedTreatmentAnxiety Disorders / Bipolar Disorder (BD) / Major Depressive Disorder (MDD) / Schizoaffective Disorders / Schizophrenic Disorders / Substance Abuse1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD)1
4CompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Bipolar Disorder (BD)1
4CompletedTreatmentAutism Spectrum Conditions/Disorders1
4CompletedTreatmentBMI >27 kg/m2 / Cardiovascular Disease (CVD) / Hyperlipidemias1
4CompletedTreatmentBipolar Disorder (BD)7
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar Disorder (BD) / Metabolic Complications1
4CompletedTreatmentBipolar Disorder (BD) / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentDSM-IV Schizophrenia / Schizoaffective Disorders1
4CompletedTreatmentDepression, Bipolar2
4CompletedTreatmentEating Disorders1
4CompletedTreatmentFirst Episode Psychosis1
4CompletedTreatmentGeneralized Anxiety Disorder (GAD) / Panic Disorders1
4CompletedTreatmentGilles de la Tourette's Syndrome / Tic Disorders1
4CompletedTreatmentInsulin Resistance / Schizophrenic Disorders1
4CompletedTreatmentIrritability Associated With Autistic Disorder1
4CompletedTreatmentMajor Depressive Disorder (MDD)3
4CompletedTreatmentOppositional Defiant Disorder1
4CompletedTreatmentParkinson's Disease (PD) / Psychosis1
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders5
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders5
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Social Anxiety Disorder (SAD)1
4CompletedTreatmentSchizophrenic Disorders19
4CompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentIdiopathic hyperprolactinemic disorder1
4Enrolling by InvitationTreatmentPsychosis / Psychotic Disorder NOS / Schizophrenic Disorders1
4Enrolling by InvitationTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4Not Yet RecruitingTreatmentAcute Schizophrenia Episode1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4Not Yet RecruitingTreatmentSchizophrenic Disorders2
4Not Yet RecruitingTreatmentTourette's Disorder (TD)1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingDiagnosticFirst Episode Psychosis / Schizoaffective Disorders / Schizophrenic Disorders1
4RecruitingOtherAttenuated Psychosis Syndrome1
4RecruitingTreatmentAntipsychotics Weight Gain1
4RecruitingTreatmentAntipsychotics / Aripiprazole / LAI / Long-Acting Injection / Schizophrenic Disorders1
4RecruitingTreatmentBipolar Disorder (BD) / Medication Adherence / Medication Non Adherence1
4RecruitingTreatmentGeriatric Depression / Late Life Depression (LLD) / Major Depressive Disorder (MDD) / Treatment Resistant Depression (TRD) / Treatment-Refractory Depression1
4RecruitingTreatmentMajor Depressive Disorder (MDD)1
4RecruitingTreatmentSchizophrenic Disorders2
4RecruitingTreatmentTreatment Resistant Major Depressive Disorder / Treatment Resistant Major Depressive Disorder Depression1
4TerminatedNot AvailableHigh Risk MC4R Genotype / Low Risk MC4R Genotype / One Week or Less Antipsychotic Lifetime Exposure1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4TerminatedTreatmentMetabolic Syndromes / Schizophrenic Disorders1
4TerminatedTreatmentMethamphetamine Dependence2
4TerminatedTreatmentPediatric Bipolar Disorder1
4TerminatedTreatmentSchizophrenic Disorders2
4TerminatedTreatmentSexual Dysfunctions1
4Unknown StatusTreatmentAutism, Early Infantile1
4Unknown StatusTreatmentBipolar I Disorder1
4Unknown StatusTreatmentBipolar / Schizophrenic Disorders1
4Unknown StatusTreatmentDyskinesia, Drug-Induced1
4Unknown StatusTreatmentDyslipidemias / Idiopathic hyperprolactinemic disorder / Weight gain therapy1
4Unknown StatusTreatmentPsychosis1
4Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4Unknown StatusTreatmentSchizophrenia or Schizoaffective Disorder1
4Unknown StatusTreatmentSchizophrenia, Tardive Dyskinesia, Metabolic Syndrome1
4Unknown StatusTreatmentSchizophrenic Disorders3
4Unknown StatusTreatmentIdiopathic hyperprolactinemic disorder / Sexual Dysfunctions1
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentDepressive Disorder Not Otherwise Specified (NOS) / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4WithdrawnTreatmentMethamphetamine Dependence1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Metabolic Syndromes / Psychotic Disorder NOS1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableNormal Volunteers1
Not AvailableCompletedNot AvailableSchizoaffective Disorders / Schizophenia Disorder1
Not AvailableCompletedNot AvailableSchizophrenic Disorders1
Not AvailableCompletedBasic ScienceAntipsychotics / Brain Metabolism / Cognition / Dopamine Receptor Occupancy1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1
Not AvailableCompletedOtherMajor Depressive Disorder (MDD)1
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depression / Psychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedTreatmentAttention Deficit Disorder With Hyperactivity (ADHD) / Bipolar Disorder (BD)1
Not AvailableCompletedTreatmentAutism, Early Infantile1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentMetabolic Syndromes1
Not AvailableCompletedTreatmentObsessive Compulsive Disorder (OCD) / Schizophrenia OCD1
Not AvailableCompletedTreatmentTrichotillomania1
Not AvailableCompletedTreatmentIdiopathic hyperprolactinemic disorder1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingNot AvailableWeight, Body1
Not AvailableNot Yet RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / Gynaecological infection / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAdverse Drug Effect of Antipsychotics and Neuroleptics / Efficacy / Individualed Opitmal Therapy / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableAnorexia Nervosa (AN) / Attention Deficit Disorder With Hyperactivity (ADHD) / Depression1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD) / First-Episode Psychosis1
Not AvailableRecruitingOtherBioequivalence1
Not AvailableRecruitingTreatmentSchizophrenic Disorders2
Not AvailableTerminatedNot AvailableSchizophrenic Disorders1
Not AvailableTerminatedOtherBipolar Disorder (BD)1
Not AvailableTerminatedTreatmentBipolar Disorder (BD) / Metabolic Syndromes1
Not AvailableTerminatedTreatmentGilles de la Tourette's Syndrome1
Not AvailableTerminatedTreatmentProdromal Psychosis / Prodromal Schizophrenia1
Not AvailableTerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders2
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders / Sensory Gating1
Not AvailableWithdrawnTreatmentPsychotic Disorder NOS1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • DispenseXpress Inc.
  • E.R. Squibb and Sons LLC
  • Murfreesboro Pharmaceutical Nursing Supply
  • Otsuka America
  • PD-Rx Pharmaceuticals Inc.
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Quality Care
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Southwood Pharmaceuticals
  • Stat Rx Usa
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular9.75 mg/1.3mL
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral2 mg/1
TabletOral2 mg
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral5 mg/1
Injection, powder, for suspension, extended releaseIntramuscular300 mg
Injection, powder, for suspension, extended releaseIntramuscular400 mg
Injection, powder, for suspension, extended release; kitIntramuscular300 mg
Injection, powder, for suspension, extended release; kitIntramuscular400 mg
Injection, powder, lyophilized, for suspension, extended releaseIntramuscular300 mg/1.5mL
Injection, powder, lyophilized, for suspension, extended releaseIntramuscular400 mg/2.0mL
Kit300 mg/1.5mL
Kit400 mg/1.9mL
SolutionOral1 mg/1mL
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
TabletOral10 mg
TabletOral15 mg
TabletOral30 mg
TabletOral5 mg
TabletOral20 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral15 mg
Tablet, orally disintegratingOral30 mg
Prices
Unit descriptionCostUnit
Abilify Discmelt 30 10 mg Dispersible Tablet Box636.3USD box
Abilify 30 mg tablet32.12USD tablet
Abilify 15 mg tablet26.07USD tablet
Abilify 10 mg tablet23.53USD tablet
Abilify 5 mg tablet23.53USD tablet
Abilify 2 mg tablet22.25USD tablet
Abilify 20 mg tablet21.99USD tablet
Abilify discmelt 10 mg tablet20.39USD tablet
Abilify discmelt 15 mg tablet20.39USD tablet
Abilify 9.7 mg/1.3 ml vial16.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006528No1994-10-202014-10-20Us
US7053092No2002-01-282022-01-28Us
US8642600Yes2002-07-282022-07-28Us
US8759350No2007-03-022027-03-02Us
US9125939No2006-07-282026-07-28Us
US9089567No2002-01-282022-01-28Us
US8017615Yes2004-12-162024-12-16Us
US8580796Yes2003-03-252023-03-25Us
US8642760Yes2003-03-252023-03-25Us
US6977257Yes2002-10-242022-10-24Us
US8518421Yes2001-07-242021-07-24Us
US7115587Yes2005-01-212025-01-21Us
US7550445Yes2005-01-212025-01-21Us
US8030313No2004-10-192024-10-19Us
US8338427No2005-03-152025-03-15Us
US8338428No2003-08-062023-08-06Us
US8759351No2003-08-062023-08-06Us
US7807680No2004-10-192024-10-19Us
US8993761No2002-09-252022-09-25Us
US8722679No2004-10-192024-10-19Us
US8399469No2005-06-292025-06-29Us
US9193685No2013-10-242033-10-24Us
US8796276No2010-06-242030-06-24Us
US9034867No2012-11-072032-11-07Us
US8431576No2010-10-262030-10-26Us
US9387182No2003-12-252023-12-25Us
US9359302No2002-09-252022-09-25Us
US9358207No2000-04-122020-04-12Us
US9526726No2015-03-192035-03-19Us
US9452131No2015-03-192035-03-19Us
US8945005No2009-08-192029-08-19Us
US8847766No2010-03-292030-03-29Us
US9787511No2014-09-192034-09-19Us
US8674825No2009-04-092029-04-09Us
US9270503No2014-09-192034-09-19Us
US9268909No2013-10-152033-10-15Us
US8956288No2009-07-062029-07-06Us
US9444503No2007-11-192027-11-19Us
US8547248No2010-12-182030-12-18Us
US9577864No2013-10-032033-10-03Us
US8545402No2010-04-272030-04-27Us
US9433371No2009-09-152029-09-15Us
US8114021No2006-11-022026-11-02Us
US9320455No2011-12-152031-12-15Us
US9119554No2008-12-162028-12-16Us
US9258035No2009-03-052029-03-05Us
US8258962No2010-11-252030-11-25Us
US7978064No2006-09-142026-09-14Us
US8718193No2009-12-052029-12-05Us
US8961412No2010-11-172030-11-17Us
US9060708No2009-03-052029-03-05Us
US9149577No2009-12-152029-12-15Us
US9941931No2010-11-042030-11-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00777 mg/mLALOGPS
logP5.21ALOGPS
logP4.9ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability49.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.992
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7431
P-glycoprotein inhibitor IInhibitor0.9585
P-glycoprotein inhibitor IIInhibitor0.9321
Renal organic cation transporterInhibitor0.5175
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6581
CYP450 2C9 inhibitorInhibitor0.6682
CYP450 2D6 inhibitorInhibitor0.6633
CYP450 2C19 inhibitorInhibitor0.8934
CYP450 3A4 inhibitorInhibitor0.5256
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9104
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.8765
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.62
hERG inhibition (predictor II)Inhibitor0.8814
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f72-0340900000-34d93478ad0d9f5cf2b0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3970100000-6b98b53e8175df39986e

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Hydroquinolones / Hydroquinolines / Dichlorobenzenes / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / Alkyl aryl ethers / Aryl chlorides / Secondary carboxylic acid amides
show 9 more
Substituents
Phenylpiperazine / N-arylpiperazine / Tetrahydroquinolone / Quinolone / Tetrahydroquinoline / 1,2-dichlorobenzene / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Alkyl aryl ether
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, dichlorobenzene, N-alkylpiperazine, quinolone (CHEBI:31236)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. [PubMed:14642974]
  2. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925]
  3. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30. [PubMed:17265076]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Partial agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90. [PubMed:16366516]
  2. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11. [PubMed:9083792]
  3. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21. [PubMed:16925992]
  4. Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28. [PubMed:16981227]
  5. Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. [PubMed:17501690]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137-40. [PubMed:12063084]
  2. Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl). 2004 Apr;172(4):415-21. Epub 2003 Nov 28. [PubMed:14647959]
  3. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004 Jan 1;483(1):45-53. [PubMed:14709325]
  4. Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. [PubMed:15257633]
  5. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005 May 10;1043(1-2):32-41. [PubMed:15862515]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name
HTR1E
Uniprot ID
P28566
Uniprot Name
5-hydroxytryptamine receptor 1E
Molecular Weight
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
11. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
12. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
13. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
14. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
15. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
Other/unknown
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:53